Skip to main content
. 2021 May 12;16:217. doi: 10.1186/s13023-021-01829-x

Table 5.

Utility values of patients treated with cerliponase alfa with mapping to the EQ-5D-3L

Disease stage Cerliponase alfa
Mean value Standard error Median value Minimum value Maximum value Difference between EQ-5D-5L and mapped EQ-5D-3L utility values
6 0.985 0.015 1.000 0.879 1.000 0.005
5 0.762 0.011 0.747 0.747 0.836 0.088
4 0.629 0.019 0.636 0.541 0.710 0.116
3 0.464 0.036 0.510 0.325 0.555 0.038
2 0.424 0.056 0.468 0.101 0.555 0.050
1 0.218 0.078 0.267  − 0.166 0.531 0.120
0  − 0.163 0.033  − 0.159  − 0.352  − 0.071 0.292
0 + VL  − 0.198 0.060  − 0.147  − 0.594  − 0.071 0.317
0 + VL + PC  − 0.211 0.058  − 0.154  − 0.594  − 0.095 0.315

Disease progression increases with decreasing disease stage. Utility values are given on a scale where 1 is equivalent to perfect health, and 0 equivalent to death. Summary values were produced from the returned EQ-5D-5L questionnaires and results were mapped to equivalent EQ-5D-3L utility values using the Van Hout algorithm [23]. UK value set

PC, palliative care; VL, vision loss